Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis

Who May Qualify: 1. Age between 18 and 65 years. 2. Total bilirubin (TBIL) \> 12 mg/dL, 3.5\>INR ≥ 1.5. 3. Meets the diagnostic criteria for sepsis 3.0: confirmed or suspected infection with an increase in SOFA score by ≥ 2 points. 4. High inflammatory state: IL-6 \> 80 pg/ml. 5. Onset of sepsis within the past 72 hours. Who Should NOT Join This Trial: 1. Presence of genetic metabolic liver disease. 2. Patients with liver malignancies or other concurrent cancers. 3. Pregnancy or lactation. 4. Patients with HIV infection or other weakened immune system diseases. 5. Patients with autoimmune conditions (where your immune system attacks your own body)s, recent cardiovascular events leading to unstable infarction, or a history of organ transplantation. 6. End-stage organ failure: End-stage chronic obstructive pulmonary disease, end-stage pulmonary heart disease, brain death, or persistent vegetative state, Grade IV hepatic encephalopathy. End-stage renal disease or acute renal failure requiring CRRT. Inability to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation, vasopressors, and steroid therapy. 7. Platelet count \< 50×10⁹/L, severe coagulopathy, or active bleeding. 8. Allergic reactions to extracorporeal circulation, hemoperfusion substances, or history of severe allergies. 9. Inability to comply with study protocols or refusal to sign the willing to sign a consent form form. 10. Inability to attend regular follow-up visits according to the study schedule. 11. Any other conditions that, in the investigator's judgment, make the patient unsuitable for inclusion in the study. Always talk to your doctor about whether this trial is right for you.